Diseases / Neuroblastoma
Neuroblastoma
DiseaseNeuroblastoma is a malignant embryonal tumor of the sympathetic nervous system that usually arises in the adrenal medulla or paraspinal ganglia and occurs predominantly in young children.
- Trials
- 650
- Recruiting
- 90
- Completed
- 330
- With results
- 121
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 5 | 1 | — | 4 | 1 | 1 | — | — | 3 | — | — | — | 15 |
| Phase 1 | 19 | 2 | 1 | 16 | 117 | 23 | 9 | 1 | 6 | — | — | — | 194 |
| Phase 1/2 | 16 | 3 | 1 | 5 | 25 | 10 | 1 | — | 4 | — | — | — | 65 |
| Phase 2 | 19 | 3 | — | 19 | 95 | 15 | 10 | — | 16 | — | — | — | 177 |
| Phase 2/3 | 2 | — | — | — | — | 2 | — | — | — | — | — | — | 4 |
| Phase 3 | 6 | — | — | 1 | 24 | 3 | — | — | 6 | — | — | — | 40 |
| Phase 4 | — | 1 | — | 1 | 1 | — | — | — | 1 | — | — | — | 4 |
| Not applicable | 6 | — | 1 | 3 | 28 | 2 | 5 | — | 11 | — | — | — | 56 |
| Unknown | 17 | 2 | 1 | 5 | 39 | 8 | 1 | — | 9 | 1 | 6 | 6 | 95 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | 15 | 194 | 65 | 177 | 4 | 40 | 4 | 56 | 95 | 650 |
| Sarcoma | — | 41 | 12 | 40 | 1 | 3 | — | 13 | 10 | 120 |
| Osteosarcoma | 1 | 51 | 15 | 35 | — | 3 | — | 5 | 6 | 116 |
| Wilms Tumor | — | 41 | 8 | 32 | — | 8 | 1 | 10 | 12 | 112 |
| Rhabdomyosarcoma | — | 38 | 14 | 32 | — | — | — | 2 | 5 | 91 |
| Medulloblastoma | 1 | 29 | 11 | 30 | — | 3 | — | 4 | 6 | 84 |
| Neoplasms | 1 | 31 | 6 | 11 | 2 | 7 | — | 11 | 15 | 84 |
| Sarcoma, Ewing | — | 33 | 13 | 24 | — | 1 | — | 2 | 6 | 79 |
| Recurrence | 1 | 27 | 12 | 12 | — | 7 | — | 8 | 8 | 75 |
| Lymphoma, Non-Hodgkin | — | 9 | 6 | 27 | — | 7 | — | 14 | 8 | 71 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 68 | 2 |
| 2 | Children's Oncology Group | 57 | 9 |
| 3 | Memorial Sloan Kettering Cancer Center | 50 | 1 |
| 4 | New Approaches to Neuroblastoma Therapy Consortium | 24 | 0 |
| 5 | St. Jude Children's Research Hospital | 23 | 0 |
| 6 | Giselle Sholler | 18 | 0 |
| 7 | Baylor College of Medicine | 14 | 0 |
| 8 | Fred Hutchinson Cancer Center | 14 | 3 |
| 9 | Children's Cancer and Leukaemia Group | 13 | 4 |
| 10 | Dana-Farber Cancer Institute | 10 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Cyclophosphamide | 101 |
| 2 | Etoposide | 60 |
| 3 | Carboplatin | 55 |
| 4 | Vincristine | 51 |
| 5 | Filgrastim | 49 |
| 6 | Doxorubicin | 44 |
| 7 | Isotretinoin | 44 |
| 8 | Melphalan | 44 |
| 9 | Temozolomide | 44 |
| 10 | Topotecan | 44 |
Evidence
- Results reported
- 36.7%121 of 330 completed
- Published
- 18.2%60 of 330 completed
- Primary endpoint met
- 62.5%10 of 16 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 38
- Median duration
- 70.9months
- Countries
- 48
- Study sites
- 2503
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 15
- Phase 1
- 24
- Phase 1/2
- 40
- Phase 2
- 40
- Phase 2/3
- 30
- Phase 3
- 360
- Phase 4
- 132
- Not applicable
- 44
- Unknown
- 125
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 150 |
| 2 | Philadelphia | United States | 121 |
| 3 | Boston | United States | 116 |
| 4 | Seattle | United States | 113 |
| 5 | San Francisco | United States | 108 |
| 6 | Cincinnati | United States | 107 |
| 7 | Houston | United States | 107 |
| 8 | Chicago | United States | 104 |
| 9 | Los Angeles | United States | 101 |
| 10 | Atlanta | United States | 95 |
Terminations
- Terminated
- 64
- Withdrawn
- 26
- Suspended
- 1
- Stopped for recruitment
- 5.1%33 of 650 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04539366 Suspended | Suspended | Other - review of safety data | 2040-12-31 |
| NCT02439788 Withdrawn | Withdrawn | Based on newly available preclinical data we changed the CAR construct to a more effective version and will now study that product on a different protocol. | 2030-10-31 |
| NCT06335745 Withdrawn | Withdrawn | Study halted prematurely, prior to enrollment of first participant | 2028-09-30 |
| NCT06182410 Withdrawn | Withdrawn | Industry sponsor decision | 2027-05-31 |
| NCT04909515 Withdrawn | Withdrawn | Study terminated due to business priorities | 2027-04-30 |
| NCT06233903 Withdrawn | Withdrawn | Logistical considerations | 2025-12-31 |
| NCT04239092 Terminated | Terminated | The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma. | 2025-07-07 |
| NCT04544995 Terminated | Terminated | Sponsor Decision | 2025-04-23 |
| NCT04023331 Terminated | Terminated | Sponsor decision | 2025-03-25 |
| NCT05429502 Terminated | Terminated | Study halted early due to high toxicity risk (from BHLRM model) in combo treatment and inability to identify recommended Phase 2 dose in initial phase (Phase 1-Part A), making continuation to subsequent phases (Phase 1-Part B and Phase 2) unfeasible. | 2025-02-26 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: